184 related articles for article (PubMed ID: 6631013)
1. Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: pretreatment with cyclophosphamide is most effective.
Livingston PO; DeLeo AB; Jones M; Oettgen HF
J Immunol; 1983 Nov; 131(5):2601-5. PubMed ID: 6631013
[TBL] [Abstract][Full Text] [Related]
2. The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants.
Livingston PO; Jones M; Deleo AB; Oettgen HF; Old LJ
J Immunol; 1985 Aug; 135(2):1505-9. PubMed ID: 4008930
[TBL] [Abstract][Full Text] [Related]
3. [Effects of levamisole on methylcholanthrene-induced tumor. I. Its antitumor effect and immunological mechanism].
Gomi K; Morimoto M; Nomoto K
Gan To Kagaku Ryoho; 1982 Jul; 9(7):1262-8. PubMed ID: 7184454
[TBL] [Abstract][Full Text] [Related]
4. [Antitumor effect of human recombinant interferon-alpha A/D in mice(I): Comparison between systemic and lesional treatment of meth-A sarcoma in BALB/c mice].
Nanjo M; Yoshie O; Aso H; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):505-9. PubMed ID: 4004283
[TBL] [Abstract][Full Text] [Related]
5. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells.
Livingston PO; Calves MJ; Natoli EJ
J Immunol; 1987 Mar; 138(5):1524-9. PubMed ID: 3805726
[TBL] [Abstract][Full Text] [Related]
6. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas.
Palladino MA; Srivastava PK; Oettgen HF; DeLeo AB
Cancer Res; 1987 Oct; 47(19):5074-9. PubMed ID: 3497717
[TBL] [Abstract][Full Text] [Related]
7. Properties of a M(r) 110,000 tumor rejection antigen of the chemically induced BALB/c Meth A sarcoma.
De Leo AB; Becker M; Lu L; Law LW
Cancer Res; 1993 Apr; 53(7):1602-7. PubMed ID: 7680955
[TBL] [Abstract][Full Text] [Related]
8. Cellular immunity to solubilized tumor antigens of a methylcholanthrene-induced sarcoma with a migration inhibition assay.
Padarathsingh ML; Dean JH; McCoy JL; Lewis DD; Northing JW; Natori T; Law LW
J Immunol; 1978 Jun; 120(6):1981-5. PubMed ID: 659888
[TBL] [Abstract][Full Text] [Related]
9. Therapy combining tumor necrosis factor with tumor-specific antibody against Meth A sarcoma.
Satomi N; Sakurai A; Haranaka R; Haranaka K
J Biol Response Mod; 1989 Oct; 8(5):528-38. PubMed ID: 2677250
[TBL] [Abstract][Full Text] [Related]
10. [Effect of different doses of cyclophosphamide on the immune response of mice with a methylcholanthrene-induced sarcoma].
Gordienko SP; Bergol'ts VM
Vopr Onkol; 1973; 19(11):54-60. PubMed ID: 4785975
[No Abstract] [Full Text] [Related]
11. Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced BALB/c sarcomas.
Coggin JH
Mol Biother; 1989; 1(4):223-8. PubMed ID: 2818874
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic properties of soluble cytosol fractions on Meth A sarcoma cells.
DuBois GC; Appella E; Law LW; DeLeo AB; Old LJ
Cancer Res; 1980 Nov; 40(11):4204-8. PubMed ID: 7471061
[TBL] [Abstract][Full Text] [Related]
13. [Effect of the rhythm of cyclophosphamide administration on its antitumor action and on the immune response of mice with methylcholanthrene-induced sarcoma].
Gordienko SP; Bergol'ts VM; Botsmanov KV
Biull Eksp Biol Med; 1974 Jul; 78(7):87-90. PubMed ID: 4451721
[No Abstract] [Full Text] [Related]
14. In vitro demonstration of complement-dependent cytotoxic antibodies to Moloney sarcoma cells.
Tamerius JD; Hellström I
J Immunol; 1974 Jun; 112(6):1987-96. PubMed ID: 4825783
[No Abstract] [Full Text] [Related]
15. Induction of antitumor immunity by tumor cells treated with abrin.
Shionoya H; Arai H; Koyanagi N; Ohtake S; Kobayashi H; Kodama T; Kato H; Tung TC; Lin JY
Cancer Res; 1982 Jul; 42(7):2872-6. PubMed ID: 7083176
[TBL] [Abstract][Full Text] [Related]
16. [Effects of levamisole on methylcholanthrene-induced tumor. II. Potentiation of cytotoxic T-cell activities].
Gomi K; Morimoto M; Nomoto K
Gan To Kagaku Ryoho; 1982 Jul; 9(7):1269-76. PubMed ID: 6985196
[TBL] [Abstract][Full Text] [Related]
17. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
[TBL] [Abstract][Full Text] [Related]
18. Serological analysis of BALB/C methylcholanthrene sarcoma Meth A by SEREX: identification of a cancer/testis antigen.
Ono T; Sato S; Kimura N; Tanaka M; Shibuya A; Old LJ; Nakayama E
Int J Cancer; 2000 Dec; 88(6):845-51. PubMed ID: 11093803
[TBL] [Abstract][Full Text] [Related]
19. IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases.
Rodolfo M; Melani C; Zilocchi C; Cappetti B; Luison E; Arioli I; Parenza M; Canevari S; Colombo MP
Cancer Res; 1998 Dec; 58(24):5812-7. PubMed ID: 9865740
[TBL] [Abstract][Full Text] [Related]
20. Dissociation between tumour resistance and delayed-type hypersensitivity to tumour-associated antigens in the mouse.
Henderson DC; Parker D; Turk JL
Immunology; 1980 Jan; 39(1):1-9. PubMed ID: 7380461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
